Literature DB >> 8933418

Specific radioimmunoassays for the measurement of stavudine in human plasma and urine.

S Kaul1, B Stouffer, V Mummaneni, N Turabi, S Mantha, P Jayatilak, R Barbhaiya.   

Abstract

Sensitive and specific radioimmunoassays (RIAs) have been developed and validated for the determination of stavudine, a nucleoside analog possessing anti-human immunodeficiency virus (HIV) activity, in human plasma and urine. The hemisuccinate of stavudine was conjugated with histamine and radioiodinated to yield the radiotracer. Antisera were produced by injecting the immunogen, stavudine-hemisuccinate-bovine thyroglobulin, into rabbits. The antisera exhibited high specificity for stavudine as the structurally related analogs and other anti-HIV agents did not interfere in the assays. The methods could reliably quantitate stavudine in plasma from 2.5-100 ng ml-1 and in urine from 5.0-1000 ng ml-1 (after 2.5-fold dilution) with good accuracy and precision. The lower limits of quantitation were 2.5 ng ml-1 in human plasma and 5.0 ng ml-1 in urine (after 2.5-fold dilution). The RIA methods were applied to the analysis of stavudine in plasma and urine obtained from HIV-infected patients receiving the drug in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8933418     DOI: 10.1016/0731-7085(96)01839-0

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  5 in total

1.  Determination of lamivudine and stavudine in pharmaceutical preparations using chemometrics-assisted spectrophotometry.

Authors:  Abd El-Maaboud I Mohamed; Workalemahu Mikre
Journal:  Saudi Pharm J       Date:  2009-11-10       Impact factor: 4.330

2.  Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection.

Authors:  S Kaul; B Christofalo; R H Raymond; M B Stewart; C M Macleod
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

3.  Determination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children with human immunodeficiency virus infection.

Authors:  S Kaul; M W Kline; J A Church; L M Dunkle
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

4.  Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.

Authors:  C Rongkavilit; P Thaithumyanon; T Chuenyam; B D Damle; S Limpongsanurak; C Boonrod; A Srigritsanapol; E A Hassink; R M Hoetelmans; D A Cooper; J M Lange; K Ruxrungtham; P Phanuphak
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

5.  Determination of ddATP levels in human immunodeficiency virus-infected patients treated with dideoxyinosine.

Authors:  Cecile Le Saint; Raphael Terreux; Daniele Duval; Jacques Durant; Helene Ettesse; Pierre Dellamonica; Roger Guedj; Jean Pierre Vincent; Anny Cupo
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.